In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 101 to 150 of 424

TitleTypeExpected publication date
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726Technology appraisal guidanceTBC
Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)NICE guidelineTBC
Diabetic retinopathy - ruboxistaurin [ID382]Technology appraisal guidanceTBC
Digital hearing aids (Provisional title)Health technology evaluationTBC
Digital platforms to support rehabilitation before and after hip or knee replacement surgeryHealth technology evaluationTBC
Digital self-help for eating disorders: early value assessmentHealth technology evaluationTBC
Digital technologies delivering CBT for insomnia and insomnia symptoms (provisional title)Health technology evaluationTBC
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early-value assessmentHealth technology evaluation
Digital technologies for multidisciplinary weight managementHealth technology evaluationTBC
Digital technologies to support asthma self-management: early value assessmentHealth technology evaluation
Digital technologies to support smoking cessation in secondary care patients: early value assessmentHealth technology evaluationTBC
Domestic violence and abuse: multi-agency workingNICE guidelineTBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidanceTBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]Technology appraisal guidanceTBC
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]Highly specialised technologyTBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Technology appraisal guidanceTBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235Technology appraisal guidanceTBC
Dupilumab for treating bullous pemphigoid [ID6479]Technology appraisal guidanceTBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]Technology appraisal guidanceTBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]NICE guidelineTBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]Technology appraisal guidanceTBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]Technology appraisal guidanceTBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]Technology appraisal guidanceTBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]Technology appraisal guidance
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Technology appraisal guidanceTBC
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]Technology appraisal guidance
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]Technology appraisal guidanceTBC
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)NICE guideline
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]Technology appraisal guidance
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Technology appraisal guidanceTBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]Technology appraisal guidanceTBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Technology appraisal guidanceTBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Endoscopic submucosal dissection knives for the removal of gastrointestinal lesionsHealth technology evaluationTBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]Technology appraisal guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]Technology appraisal guidanceTBC
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidanceTBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]Technology appraisal guidance
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]Technology appraisal guidance
Epilepsies in children, young people and adultsNICE guidelineTBC
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]Technology appraisal guidanceTBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Technology appraisal guidanceTBC
Ex-situ machine perfusion devices for deceased donor liver transplantsHealth technology evaluation

Results per page

  1. 10
  2. 25
  3. 50
  4. All